ABSTRACT
This chapter discusses the individual agents and their clinical pulmonary manifestations and management. In the field of cancer chemotherapy, additional novel compounds have been developed that inhibit a variety of different targets, including tyrosine kinases, serine-threonine kinase and the proteasomes. Interferons are a family of related glycoproteins with antiviral and immunomodulatory properties. Interleukin-2 is an endogenous cytokine that is produced by activated T-cells and natural killer cells and has direct activating effects on several subsets of immune cells. Granulocyte colony-stimulating factor is a haematopoietic growth factor that is used to stimulate neutrophil recovery following chemotherapy-induced myelosuppression. Clinical experience with macrophage colony-stimulating factor is fairly limited, as its specificity for cells of the monocyte lineage has prevented broad clinical utility. Bevacizumab is a humanized monoclonal antibody that selectively binds vascular endothelial growth factor, the major regulator of angiogenesis. Gemtuzumab ozogamicin is a humanized anti-CD33 monoclonal antibody linked to a semisynthetic derivative of cali-cheamicin, a cytotoxic antibiotic.
